Jade Biosciences
JBIO
47 hedge funds and large institutions have $302M invested in Jade Biosciences in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 6 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
15% more funds holding
Funds holding: 41 → 47 (+6)
0.46% more ownership
Funds ownership: 2.53% → 2.99% (+0.46%)
33% less capital invested
Capital invested by funds: $453M → $302M (-$151M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.57M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$2.6M |
| 3 |
FAM
Fred Alger Management
New York
|
+$2.41M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$1.47M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$626K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$15M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.52M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.89M |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$1.53M |
| 5 |
Millennium Management
New York
|
-$1.47M |
JBIO Hedge Fund Activity: Q4 2021 in Review
47 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q4 2021, worth a combined $302M — down 33% from $453M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new JBIO positions and 6 closed out — a net gain of 6 holders — while 16 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $3.57M. The largest seller was Deerfield Management, exiting entirely with an estimated $15M sold.
- 47 institutional investors held Jade Biosciences (JBIO) as of Q4 2021, up from 41 in Q3 2021.
- Funds reported $302M of Jade Biosciences stock for Q4 2021, down 33% quarter-over-quarter.
- 12 funds opened new Jade Biosciences positions in Q4 2021 and 6 closed out, a net change of +6 holders.
- The largest Jade Biosciences buyer in Q4 2021 was BlackRock, an estimated $3.57M added.
- The largest Jade Biosciences seller in Q4 2021 was Deerfield Management, an estimated $15M sold.
Based on aggregated 13F filings for Q4 2021.